J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions
J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.
You may also be interested in...
"It's amazing with this consumer empowerment how fast that market is growing," biopharma industry veteran Fred Hassan remarks. "Coming up with good products, scientifically validated, supported by doctors and approaching consumers with proper claims, it's a huge opportunity."
OTC drugs’ quick treatment of acute conditions outweighs risks from absence of physician oversight, says OTC switch consultant Bernie Simone. At CHPA regulatory conference, he discussed other drug categories during his presentation on the downside of keeping some drug ingredients Rx-only.
Glanbia subsidiary marketing SlimFast plans to appeal National Advertising Division decision, following a challenge by Atkins marketer Simply Good, finding a “clinically proven” packaging claim based on evidence from discontinued products isn’t substantiated.